Bristol Myers Squibb Says Sub-Study Of Phase 3 CheckMate-901 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that a sub-study of its Phase 3 CheckMate-901 trial met its dual primary endpoints of overall survival and progression-free survival. The study showed that Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated significant benefits compared to standard-of-care cisplatin-based combinations for patients with unresectable or metastatic urothelial carcinoma.
July 11, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the Phase 3 CheckMate-901 trial sub-study could potentially boost Bristol Myers Squibb's stock in the short term as it indicates the effectiveness of their drug, Opdivo.
Positive clinical trial results often lead to an increase in a pharmaceutical company's stock price. The successful results of the CheckMate-901 trial indicate that Opdivo could become a leading treatment for urothelial carcinoma, potentially leading to increased revenues for Bristol Myers Squibb.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100